Duke Street Bio raises £10.8m for precision cancer therapy development

Targeting DNA Damage Repair deficiencies in cancer is the primary objective of Duke Street Bio, which has recently secured an estimated £10.8m in fresh capital. The London-based biotechnology company specializes in precision medicine, specifically the development of next-generation small molecule therapies designed to exploit genetic vulnerabilities within tumors.

Incorporated in 2020, Duke Street Bio aims to improve patient outcomes by delivering treatments that harness the immune system alongside targeted genetic interventions. The company's research and development efforts are centered on identifying and treating specific weaknesses in cancer cell DNA.

This latest £10.8m investment follows a series of funding rounds over the past six years. The company previously raised £10m in January 2024. Prior to that, it secured £7.5m in May 2023 and another £7.5m in May 2022. Its earlier capitalization includes a £6.8m round in June 2021, a £100k injection in May 2021, £284k in September 2020, and an initial £999.5k in July 2020.

Financial records for the year ended 30 April 2025 show the company maintained a staff of six employees. More recent data from LinkedIn suggests the workforce has grown to ten people. The company operates its research and experimental development activities from its headquarters in London.

The documentation for this funding round was filed in May 2026, with the allotment of shares also occurring during the same month. Duke Street Bio continues to focus on its core mission of developing life-saving treatments through its specialized biotechnology platform.